RxDoctor Payments Data

Rehan Khan, MD

Physical Medicine & Rehabilitation · Bel Air, MDNPI 1497796619

Payments from drug & device makers

What this record shows

9 manufacturers reported payments, led by Merck at 52.8% of the total. Reporting peaked in 2023 at $1,074 and has fallen 61.1% since, to $418 in 2024.

$1,749in general payments, 2019–2025

Across 20 payments — averaging $87.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$924
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$241
  • AstraZeneca$121
  • Collegium Pharmaceutical, Inc.$118
  • Averitas Pharma Inc.$90
  • Pfizer$82
  • plus $174 from 3 others

What the payments were for

  • Travel & lodging$74843%
  • Food & beverage$1,00257%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,749 in reported general payments places this provider in the 80th percentile of 202 physical medicine & rehabilitation providers in Maryland.

See all physical medicine & rehabilitation providers in Maryland

Medicare billing

Part B allowed, 2024
$45,154
Medicare patients
45
Services billed
445

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl69$27,610
Xtampza ErOxycodone Myristate16$9,281
Hysingla ErHydrocodone Bitartrate13$4,191
Oxycodone Hcl206$2,440
Tramadol Hcl ErTramadol Hcl14$1,009
Tramadol Hcl98$485
Methadone Hcl42$468
Gabapentin45$445
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen18$315
Morphine Sulfate ErMorphine Sulfate37$292
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen28$267
Celecoxib15$166
Baclofen12$109
Naproxen12$86
Amoxicillin12$31

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$118$9,28116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 202 physical medicine & rehabilitation providers in Maryland.

Other physical medicine & rehabilitation in Bel Air

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →